The Efficacy of Scalp-Cooling System for the Prevention of Chemotherapy-Induced Hair Loss in Metastatic Breast Cancer Patients Treated with Eribulin

In a study conducted at the Kato Breast Surgery Clinic, the efficacy of a scalp-cooling system (RV-01) was evaluated for preventing chemotherapy-induced alopecia (CIA) in 20 patients with metastatic breast cancer undergoing treatment with eribulin. The study found that none of the 16 patients who used the RV-01 system required a wig, with hair loss ranging from Grade 0 to Grade 1 on the NCI-CTC scale and Grade 0 to Grade 3 on Dean's scale. The system, which includes a digitized control unit and a silicon cap, was well-tolerated with minimal discomfort reported. The use of an inner cap made of non-woven fabric was noted to increase comfort. The study concluded that scalp hypothermia using the RV-01 is a simple and effective method to prevent hair loss in patients treated with eribulin, potentially improving their quality of life and aiding in their treatment. The study did not receive any funding and there were no conflicts of interest declared.